



## MannKind's Chairman and CEO Recognized as One of PharmaVOICE's "100 Most Inspiring People in the Life Sciences"

August 3, 2010 4:00 AM EDT

### MannKind's Chairman and CEO Recognized as One of PharmaVOICE's "100 Most Inspiring People in the Life Sciences"

VALENCIA, Calif., Aug 03, 2010 (BUSINESS WIRE) --

MannKind Corporation (Nasdaq: MNKD) today announced that the company's chairman and CEO Alfred E. Mann has been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences." Mr. Mann was recognized for his extraordinary leadership and passion in his lifelong roles as a scientist, inventor, entrepreneur and philanthropist, for which he has received more than 70 honors from the public and private sectors, including life achievement and humanitarian awards. He was nominated to the list by peers, colleagues and friends who have worked with him throughout his career and who describe him as "boundlessly visionary and persistent." Throughout Mr. Mann's nearly 60 years in the life sciences industry, the octogenarian billionaire has founded 17 companies, devoting his professional life to developing innovative medical products and technologies to satisfy the unmet needs of patients with health issues ranging from diabetes and heart disease to hearing impairment and chronic pain.

"It is our extreme pleasure to once again be able to pay tribute to the men and women who are driving change, providing guidance, and fostering relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients," said Taren Grom, editor-in-chief and cofounder of PharmaVOICE.

Mr. Mann has made it his personal mission to identify a solution for the current global diabetes epidemic, which affects 246 million people worldwide. Following this vision, in 2001 Mr. Mann formed MannKind Corporation, which, under his guidance, developed the ultra rapid-acting mealtime insulin therapy, AFREZZA (insulin human [rDNA origin]) Inhalation Powder. Mr. Mann is passionate about the promise that this investigational therapy holds for the diabetes community. A New Drug Application (NDA) requesting approval of AFREZZA for the treatment of adults with Type 1 or Type 2 diabetes for the control of hyperglycemia is currently under review by the U.S. Food and Drug Administration (FDA).

"I am truly honored to have been included in this year's PharmaVOICE 100 list, and would like to express my appreciation to all those who nominated me," said Mr. Mann. "While I have many experiences to be thankful for and successes to be proud of, my hope is that my biggest career highlight is yet to come."

Born in Portland, Oregon, Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles, and his first industry job was as a research physicist at Technicolor Corporation in 1951. Mr. Mann went on to receive honorary doctorate degrees from the University of Southern California, Johns Hopkins University, Western University and the Technion-Israel Institute of Technology. Together with his wife, Claude, he enjoys classical music and has made numerous philanthropic contributions to the arts. He has seven children and 10 grandchildren.

"AI has been the guiding force behind the development of AFREZZA," said Hakan S. Edstrom, President and Chief Operating Officer, MannKind Corporation. "He is a constant source of vision and leadership, and an inspiration to everyone at MannKind, and for these and other qualities he certainly deserves this recognition."

Mann's charitable contributions are as impressive as his professional ones. He founded and endowed the Alfred Mann Foundation, which develops medical products to fill poorly-met medical needs, and also founded medical research institutes at the University of Southern California, Purdue University and the Technion-Israel Institute.

Mr. Mann is featured in the sixth annual PharmaVOICE 100 issue, which is the July/August 2010 issue of the publication.

#### About the PharmaVOICE 100

Established six years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. The distinguished honorees are nominated by thousands of PharmaVOICE readers. The PharmaVOICE 100 represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, regulatory, technology, and many others. Furthermore, the leaders chosen as this year's most inspiring representatives within the industry have accomplishments that are diverse; this group of thought leaders contribute to the growth and well-being of not only their companies, but to their communities as well as varied industry associations.

#### About AFREZZA

AFREZZA is a novel, ultra rapid-acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with Type 1 and Type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder pre-metered into single use cartridges and the light, discreet and easy-to-use AFREZZA Inhaler. Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly to the blood stream. Peak insulin levels are achieved within 12 to 14 minutes of administration, mimicking the release of meal-time insulin observed in healthy individuals. To date, the AFREZZA clinical program has involved more than 50 different studies and over 5,000 adult patients.

#### About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials.

MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MCS Healthcare Public Relations

Alanna Jamieson, 908-234-9900

[alannaj@mcspr.com](mailto:alannaj@mcspr.com)